This company has shut down. Reneo Pharmaceuticals is no longer operating — its last tracked round was a Post-IPO Equity in 2023.
Explore the Startup GraveyardReneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.
Reneo Pharmaceuticals has raised $55.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2023.
Reneo Pharmaceuticals's investors include New Enterprise Associates, Abingworth, Rock Springs Capital, RiverVest, Aisling Capital.
Reneo Pharmaceuticals is headquartered in San Diego, United States.
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.
Reneo Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Reneo Pharmaceuticals — Funding & Investors." VCBacked, May 3, 2023, https://www.vcbacked.co/company/reneo-pharmaceuticals. Accessed August 14, 2026.
VCBacked. (2023). Reneo Pharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/reneo-pharmaceuticals
{{cite web |title=Reneo Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/reneo-pharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated